Syneos - Commercial - ProdNewPayor Medical Science Liaison Syneos - Commercial - ProdPayor Medical Science LiaisonKansas City, MO$180,000–$197,500 / yearIn addition the role may engages in peer-peer scientific and health economic discussions with relevant health care decision makers (HCDMs) and influencers within US public and private health care entities, including but not limited to, managed care organizations (MCOs), specialty pharmacy providers (SPPs), pharmaceutical benefit managers (PBMs), integrated delivery networks (IDNs), at designated centers and other health care networks. Delivers scientific presentations to formulary committees and other key healthcare decision makers (HCDMs), communicating the health economic model and supporting clinical data, and serves as the primary field-based resource to address questions related to these insights.
Taylor Strategy PartnersNewSpecialty Sales Representative – Cardiometabolic Rare Disease Taylor Strategy PartnersSpecialty Sales Representative – Cardiometabolic Rare DiseaseKansas City, KSRemote$160,000–$180,000 / yearThis is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high-need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.
Taylor Strategy PartnersNewSpecialty Sales Representative - Cardiometabolic Rare Disease Taylor Strategy PartnersSpecialty Sales Representative - Cardiometabolic Rare DiseaseKansas City, MORemote$160,000–$180,000 / yearThis is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high-need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.